



CLX Investment Company, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

September 2007 Newsletter

CLX Investment Company Increases Equity Interest in Zonda with Purchases of Additional Ownership Percentage

Acquisition of Additional 15% Brings Total Equity Position in Zonda to 46%

During the month of August 2007, CLX Investment Company (stock symbol OTC BB: CLXN) acquired another 15% of the issued and outstanding shares of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets, bringing the company's total equity position in Zonda to 46%. The additional 15% was acquired from three of Zonda's minority shareholders in exchange for restricted common stock.

By acquiring an larger equity interest in Zonda, CLX management has stated that CLX is better positioned as the companies move forward with CLX's anticipated acquisition of the remaining issued and outstanding shares of Zonda.

CLX and Zonda have entered into an initial agreement in the form of a letter of intent under which CLX would acquire the remaining issued and outstanding shares of Zonda (See story on page 4). Once the remaining due diligence is complete, the companies expect to reach a definitive agreement regarding the acquisition.

Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.

Zonda's strong intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. The company's first medical test for *Chlamydia* is currently sold throughout Europe under the HandiLab brand and is expected to launch in the U.S. at the end of the first quarter 2008. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.

"As CLX works to complete the due diligence necessary before executing a definitive agreement to acquire the remaining ownership percentage of Zonda, we are pleased to increase our total equity position to 46%," said Steven R. Peacock consultant CEO of CLX Investment Company.

Inside This Issue

CEO Greeting
Page 2

*Appointment of Vera Leonard as
New CEO for Zonda, Incorporated*
Page 2

*Q & A With Zonda CEO, Vera
Leonard*
Page 3

*CLX Reaches Initial Agreement
for Acquisition of Remaining
Outstanding Shares of Zonda*
Page 4

*ActionView International Signs
Agreement for Reverse Merger
Transaction*
Page 4


About the Company

CLX Investment Company, Inc. (OTC BB: CLXN) is a holding company seeking to provide long-term value for its shareholders by executing an acquisition strategy.

CLX owns a 46% equity interest in Zonda, Incorporated (www.zondaincusa.com), a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. CLX also holds a common stock position in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded company that designs, develops, and manufactures vividly illuminated motion billboards.

Vera Leonard Appointed CEO for Zonda, Incorporated

Vera Leonard, an executive with significant experience in leadership positions with major medical manufacturing and distribution companies, has been appointed to the position of chief executive officer of Zonda, Incorporated, in which CLX holds a 46% equity interest. Zonda (www.zondaincusa.com) is a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets.



As vice president of U.S. sales for a Nasdaq listed company that specializes in rapid, point-of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately \$8 million in annual revenue and helped to grow revenues from \$32 million to \$51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than \$1,500,000 annually for the company from renegotiations of growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees.

Ms. Leonard received awards for outstanding sales performance and distribution partnering from industry-leading distributors three years in a row and for four years total. She restructured the sales and support organization to establish elevated standards of performance, goal-driven compensation plan, territory-level budget and forecast management while developing individuals for promotion to levels of greater responsibility and leadership.

Ms. Leonard also served as director of vendor relations for a Fortune 500 distributor of medical and dental supplies to office-based practices worldwide. In this position, she launched 6 new products; negotiated semi-exclusive distribution rights on three innovative new products; designed a product launch template that was adopted for standard use by the entire medical marketing team; negotiated an exclusive special pricing agreement on market-leading product to maximize competitive conversions; and completed an in-depth pricing analysis by vendor, sales division and SKU to assess pricing strategies and assure competitive positioning while maximizing profitability.

(continued on page 3)

Greetings from the CEO

Although there were not a large number of press releases issued by CLX Investment Company over the past month to include in our September 2007 investor newsletter, there is quite a bit of activity going on behind the scenes.

As our press releases of August 15 and August 28 indicate, CLX has prioritized the acquisition of a larger percentage of Zonda, Incorporated as part of its strategy to deliver long-term value to CLX shareholders. We will keep CLX shareholders updated on where Zonda will fit into the big picture strategy for the company in the coming weeks, but at this point are pleased to see the initial steps that Zonda's new CEO, Vera Leonard, has taken to chart an effective course for Zonda to reach its full potential in the medical diagnostic testing field.

Speaking of Ms. Leonard, this newsletter includes a Question & Answer article in which she addresses three significant questions related to Zonda, its potential in the medical diagnostic testing market, her background in this field, and why she was attracted to the Zonda opportunity. Not surprisingly, her beliefs about the potential of Zonda are very similar to the conclusions of the CLX Board of Directors when they originally made an investment in Zonda back in 2005. CLX management continues to feel that Zonda, with the addition of Vera Leonard as CEO, can become a major player in the rapid medical diagnostics market.

Also included in our September newsletter is our recent press release regarding a major announcement by ActionView International.

(continued on page 3)

Safe Harbor Statement

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Q & A With New Zonda CEO, Vera Leonard

CLX Investment Company, Inc. recently announced the appointment of Vera Leonard to the position of chief executive officer of Zonda, Incorporated. CLX currently holds a 46% equity interest in Zonda, a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. Ms. Leonard has extensive successful experience in the medical manufacturing and distribution field.

The following questions were posed to Ms. Leonard after her appointment to the CEO position.



What in your background makes you particularly well suited for the CEO position for Zonda, Incorporated?

From my first career as a Registered Medical Technologist through almost 30 years in medical sales and sales management, rapid diagnosis of patients' conditions has been a focus of my work. I understand well that any tool that helps a healthcare practitioner identify the cause of a person's condition has great merit – and marketability. I come from a medical family with two brothers who are M.D.s in active practice and have seen the need from their perspective firsthand. Having led successful sales teams in companies such as SmithKline Diagnostics (now Beckman Coulter), Boehringer Mannheim (now Roche Diagnostics) and Quidel Corporation, I have experienced launching new and innovative products while helping the company exceed its financial and market share goals. As Vice President of U.S. Sales at Quidel Corporation, we were able to meet or exceed market expectations for an unprecedented six successive quarters, achieve market leadership in four of our six product categories and win awards for outstanding performance from the country's three leading medical distribution companies. My goal is to achieve the same level success at Zonda.

What did you see in Zonda that attracted you to this opportunity?

I was first attracted by the possibility of a point-of-care test for Chlamydia that might meet the FDA requirements for CLIA waiver. Having CLIA waiver status would allow virtually thousands of doctors to screen their patients for this disease. You know, of course, that Chlamydia is the number one sexually transmitted disease in this country. It is asymptomatic, so many people don't even know they have it and spread it unknowingly. CDC guidelines call for all sexually active females under the age of 26 to be screened annually for Chlamydia,

(continued on page 4)

Vera Leonard Appointed Zonda CEO

(continued from page 2)

Previous to these positions, Ms. Leonard served as sales representative, sales manager, regional sales manager, and national sales manager for medical manufacturing and distribution companies where she developed an extensive firsthand knowledge of the medical supply field. These companies ranged from start-ups to major U.S. and international firms.

"We are extremely pleased to see that Zonda has engaged an executive of the caliber of Vera Leonard to build on its initial success and bring it to the next level," commented Steven R. Peacock, consultant CEO of CLX Investment Company. "Zonda figures prominently in CLX's plans to deliver value to shareholders, and we look forward to working with Ms. Leonard to achieve this goal."

Greetings from the CEO

(continued from page 2)

As a reminder to shareholders, CLX owns over 6 million shares of ActionView International common stock. ActionView has announced an agreement to become the public vehicle for the entrance of Dalian Chuming Group Co., LTD, a major pork producer in China, into the U.S. markets. The preliminary agreement calls for ActionView International to serve as the public company for Dalian Chuming Group to become a U.S. public company under a reverse merger scenario.

We expect that September will be a very active month for CLX, and we hope that our shareholders will continue to follow our progress through this newsletter and upcoming press releases. Shareholders should already be subscribed to our Email Alerts, which can be found on the CLX website at www.clxinvestments.com/email.php so they receive new information from the company immediately after it is disclosed.

Regards,
Steven R. Peacock, Consultant CEO

Q & A With New Zonda CEO, Vera Leonard

(continued from page 3)

but as yet, there is no test available that makes that possible. Our test could be the first point-of-care test to offer the accuracy, ease of use, and price point to meet that need. That's huge! That's where my interest and first conversations with Zonda centered. When I realized that the technology was itself revolutionary, I knew that this was a company I wanted to work with. What Zonda has developed, its enzymatic detection technology, has the potential of being the cutting-edge new technology the market has needed.

What do you see as the future potential of Zonda and its medical diagnostic testing products?

We are working now toward achieving FDA clearance of the Chlamydia product. With that accomplished, we will have established and validated a new, superior technology for the rapid diagnosis of disease. Our plan is to follow the launch of the Chlamydia device with a submission for CLIA waiver. This will blaze the path for the launch of our next products for gonorrhea, yeast (Candida) and Group A Strep. These are significant products, each of which addresses a multi-million dollar market.

-- The incidence of reported Gonorrheal infections in the United States increased in 2005 for the first time since 1999. It is the second most commonly reported notifiable disease in the United States. CDC estimates that 700,000 people contract new cases of gonorrhea each year.

-- Nearly 75% of all adult women will experience a genital yeast infection in their lifetime. However, misdiagnosis is common, and studies have shown that as many as two-thirds of all over the counter drugs sold to treat yeast infections were used by women without the disease. Accurate diagnosis is crucial since overuse of these antifungal medications can increase the chance that they will eventually not work (the fungus develops resistance to medications). Therefore, it is important to be sure of the diagnosis before treating with over-the-counter or other antifungal medications.

-- The chlamydia, gonorrhea, and yeast markets are not only growing markets but are markets we believe are underserved by existing technology. The Group A Strep market is well established, but with annual market revenues in excess of \$75 million, we believe our unique technology will offer opportunity to garner significant market share.

All in all, I believe the potential is here for Zonda to become a major player in the rapid diagnostics market and it would be great fun to lead the charge!

CLX Investment Company Announces Initial Agreement to Acquire Zonda, Incorporated

CLX Investment Company, Inc. has entered into an initial agreement in the form of a letter of intent to acquire the remaining issued and outstanding shares of Zonda, Incorporated, which develops and manufactures unique diagnostic tests for both the medical and non-medical markets. Once the remaining due diligence is complete, the companies expect to reach a definitive agreement regarding the acquisition.

Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point-of-care, and the over-the-counter (OTC) markets.

CLX recently acquired an additional 10% of the issued and outstanding shares of Zonda, bringing its total equity position to 41%. The company subsequently announced the acquisition of another 5%. Under terms of the letter of intent, the result of the transaction is expected to result in CLX acquiring the remaining 54% of Zonda.

"Zonda is an ideal acquisition candidate for CLX, and we look forward to rapidly completing the due diligence process, so a definitive agreement can be executed as soon as possible," stated Steven R. Peacock, consultant chief executive officer of CLX Investment Company.

CLX Alerts Shareholders of ActionView International's Announced Reverse Merger Transaction

CLX has alerted its shareholders that ActionView International, in which CLX owns over 6 million shares of common stock, has announced an agreement to become the public vehicle for the entrance of Dalian Chuming Group Co., LTD, a major pork producer in China, into the U.S. markets.

Dalian Chuming Group Co., LTD is a private Chinese company that is seeking a listing in the U.S. public markets through a reverse merger transaction.

Dalian Chuming Group Co., LTD (www.chuminggroup.com) is a major producer and exporter of fresh and frozen pork and other cooked meat products. The Chuming Group is among a select group of industrialized farming corporations in northeastern China and is known for its international quality management standards and international safety certifications. In late 2006, the company officially opened a \$2.9 million feedmill with a capacity of 200,000 tons per year that will support its expansion of pork production. The pursuit of a U.S. public listing is expected to allow the Chuming Group to expand into additional worldwide markets.